Phase 2 Renal Cell Carcinoma (RCC) Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb254 enrolled72 locationsNCT07293351
Recruiting
Phase 2
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Renal Cell Carcinoma (RCC)Small Cell Lung CancerNon-Small-Cell Lung
Advenchen Pharmaceuticals, LLC.80 enrolled7 locationsNCT05363280
Recruiting
Phase 2
Cabozantinib Dose Skipping as an Alternative to Dose Reductions
Renal Cell Carcinoma (RCC)
dr. Tom van der Hulle34 enrolled1 locationNCT07077161
Recruiting
Phase 2
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Renal Cell Carcinoma (RCC)
Tianjin Medical University Second Hospital40 enrolled1 locationNCT07172386
Recruiting
Phase 2
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
Renal Cell Carcinoma (RCC)Metastatic Renal Cell Carcinoma (mRCC)
Jinling Hospital, China30 enrolled1 locationNCT07175480
Recruiting
Phase 1Phase 2
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Advanced Solid Tumor+3 more
GI Innovation, Inc.76 enrolled3 locationsNCT07172802
Recruiting
Phase 2
Ablative Radioembolization of Renal Cell Carcinoma Trial
Renal Cell Carcinoma (RCC)Radioembolization
Derek W. Cool16 enrolled1 locationNCT06642220
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
HER2-negative Breast CancerAdvanced Solid TumorMetastatic Solid Tumor+6 more
GI Innovation, Inc.358 enrolled11 locationsNCT05824975